Fibrocell Science (FCSC) Updates on Azficel-T Wind-Down; Expects 'Significant' Cost Savings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- Lockheed Martin to acquire Ultra Maritime for $3.45 billion
- UK budget airline easyJet ready to accept $7.3 billion takeover bid from Castlelake
- Strategy reports $8.32B bitcoin loss and sells BTC to fund dividends
Fibrocell Expects Significant Cost Savings from Wind-Down of azficel-T Operations
June 29, 2016 4:30 PM EDTEXTON, Pa., June 29, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC) today announced significant cost savings are expected from the wind-down of its azficel-T operations and that the Company is focusing its efforts and resources on its gene therapy portfolio of product candidates that are developed in conjunction with Intrexon CorporationFCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), FCX-013 for the treatment of linear scleroderma, and genetically-modified fibroblasts for the treatment of arthritis and related conditions.
We believe our innovative gene therapy programs have the potential to be transformative for... More
